Accessibility Menu
SIGA Technologies logo

SIGA Technologies(NASDAQ) SIGA

Current Price$3.14
Market Cap$243.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-0%
5 Year-20%
1 Year-50%
1 Month-27%
SIGA Technologies last closing stock price
MetricPriceDate
Last closeUSD 3.152026-07-23
SIGA Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.52%USD 3.562026-07-16
1 month-26.74%USD 4.302026-06-23
3 month-31.07%USD 4.572026-04-24
Year to date-41.72%USD 5.412025-12-31
1 year-50.27%USD 6.332025-07-23
3 year-16.9%USD 3.792023-07-24
5 year-19.62%USD 3.922021-07-23
Since inception-0.32%USD 3.401997-09-09

SIGA Technologies Financials at a Glance

Market Cap

$243.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$93.78M

Net Income (TTM)

$20.26M

EPS (TTM)

$0.28

P/E Ratio

12.04

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$3.14

Volume

40,475

Open

$3.35

Previous Close

$3.14

Daily Range

$3.10 - $3.35

52-Week Range

$3.10 - $8.51

Estimated Earnings Date

Aug 4, 2026

SIGA: Motley Fool Moneyball Superscore

46

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SIGA Technologies

SIGA Technologies develops antiviral drugs for infectious diseases. Its main product, TPOXX, treats smallpox. The company partners with Cipla for antibacterial drug innovation.

Products and Services

TPOXX (Tecovirimat): Oral and intravenous smallpox treatment.

Regulatory Approvals: Approved by FDA, EMA, Health Canada, MHRA, and PMDA.

International Sales: Delivered to 13 countries in 2024.

Government Contracts: Significant contracts with U.S. agencies like BARDA and DoD.

Strategic Partnerships: Collaboration with Cipla for antibacterial drugs.

Growth and Expansion

Strategic partnership with Cipla Therapeutics for antibacterial drug innovation.

International Promotion Agreement with Meridian for regional sales expansion.

Ongoing trials for TPOXX in mpox treatment.

What Makes SIGA Special

SIGA's global reach is bolstered by broad regulatory approvals and strategic partnerships. Its focus on government contracts provides a stable revenue base.

Five Things You Need to Know

2024 international sales reached $23.0 million.

U.S. Department of Defense sales in 2024 totaled $10 million.

Significant revenue from BARDA and DoD contracts.

Manufacturing relies on third-party CMOs like Grace and Catalent.

2024 revenue from oral TPOXX was $396.9 million.

Bottom Line

SIGA Technologies leverages strategic partnerships and government contracts to drive growth. Its focus on health security positions it uniquely in the pharmaceutical industry.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Employees

49

CEO

Diem Nguyen, PhD, MBA

Headquarters

New York City, NY 10065, US

SIGA Financials

Key Financial Metrics (TTM)

Gross Margin

65.35%

Operating Margin

22.00%

Net Income Margin

21.61%

Return on Equity

10.62%

Return on Capital

11.88%

Return on Assets

9.24%

Earnings Yield

8.31%

Dividend Yield

0.00%

Payout Ratio

2.14%

Stock Overview

Market Cap

$243.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

71.72M

Volume

40.48K

Avg. Volume

531.88K

Financials (TTM)

Gross Profit

$61.29M

Operating Income

$20.64M

EBITDA

$27.50M

Operating Cash Flow

$27.75M

Capital Expenditure

-$330.12K

Free Cash Flow

$27.42M

Cash & ST Invst.

$145.56M

Total Debt

$638.23K

SIGA Technologies Performance Analysis

SIGA Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 110,775,610-17.1%
20232023-12-31USD 139,917,22026.3%
20242024-12-31USD 138,719,350-0.9%
20252025-12-31USD 94,574,902-31.8%
SIGA Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301052.1%
Q32025-09-30-96.8%
Q42025-12-3145.0%
Q12026-03-3164.3%
SIGA Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.46-49.9%
20232023-12-31USD 0.95108.4%
20242024-12-31USD 0.82-13.3%
20252025-12-31USD 0.32-60.7%
SIGA Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308696.5%
Q32025-09-30-118.4%
Q42025-12-3116.2%
Q12026-03-3136.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.24M

-11.3%

Gross Profit

$3.30M

-52.0%

Gross Margin

52.89%

N/A

Market Cap

$243.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.96M

N/A

Employees

49

N/A

Net Income

-$3.45M

-746.2%

EBITDA

-$3.89M

-794.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$145.56M

-10.3%

Total Debt

$638.23K

+14.2%

Accounts Receivable

$4.50M

-37.4%

Inventory

$56.49M

-4.3%

Long Term Debt

$100.00K

N/A

Short Term Debt

$538.23K

-3.7%

Return on Assets

9.24%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

-$8.66M

-223.1%

Operating Cash Flow

-$8.66M

-222.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORGOOrganogenesis Holdings Inc.
$2.43-1.62%
SNDLSNDL Inc.
$1.25-1.57%
AQSTAquestive Therapeutics, Inc.
$3.77-4.31%
EBSEmergent BioSolutions Inc.
$7.50-1.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
AALAmerican Airlines Group
$13.56-0.08%
TAT&T
$22.96-0.00%

Questions About SIGA

What is the current price of SIGA Technologies?

SIGA Technologies is trading at $3.14 per share.

What is the 52-week range for SIGA Technologies?

Over the past 52 weeks, SIGA Technologies has traded between $3.10 and $8.51.

How much debt does SIGA Technologies have?

As of the most recent reporting period, SIGA Technologies reported total debt of $638.23K.

How much cash does SIGA Technologies have on hand?

SIGA Technologies reported $145.56M in cash and cash equivalents in its most recent financial results.

What is SIGA Technologies’s dividend yield?

SIGA Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.